Tumor necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma

Neoplasia

Volumn 9, Issue 11, 2007, Pages 987-992

  Jeng, Jen Eing ^a,b   Tsai, Jung Fa ^a,b   Chuang, Lee Yea ^b   Ho, Mei Shang ^c   Lin, Zu Yau ^a,b   Hsieh, Min Yuh ^a,b   Chen, Shin Chern ^a,b   Chuang, Wan Lung ^a,b   Wang, Liang Yen ^a,b   Yu, Ming Lung ^a,b   Dai, Chia Yen ^a,b   Chang, Jan Gowth ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Hepatic fibrosis; Hepatocellular carcinoma; Risk factor; Single nucleotide polymorphism; Tumor necrosis factor

Indexed keywords

ALBUMIN; DNA; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA 308.2; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

EID: 36049033413     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07781     Document Type: Article

References (56)

1. Bosch FX, Ribes J, Diaz M, and Cleries R (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S16.
2. Donato F, Gelatti U, Limina RM, and Fattovich G (2006). Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 25, 3756-3770.
3. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, and Tsai JH (1997). Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 76, 968-974.
4. Kremsdorf D, Soussan P, Paterlini-Brechot P, and Brechot C (2006). Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25, 3823-3833.
5. Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, and Stuver SO (2006). Alanine aminotransferase level as predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 119, 192-195.
6. Levrero M (2006). Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25, 3834-3847.
7. Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen WL, Chuang WL, Wang LY, et al. (2004). Habitual betel quid chewing and risk for hepatocellular carcinoma complicating cirrhosis. Medicine 83, 176-187.
8. Cha C and DeMatteo RP (2005). Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 19, 25-37.
9. Koziel MJ (1999). Cytokines in viral hepatitis. Semin Liver Dis 19, 157-168.
10. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77, 68-76.
11. Chuang E, Del Vecchio A, Smolinski S, Song XY, and Sarisky RT (2004). Biomedicines to reduce inflammation but not viral load in chronic HCV: what's the sense? Trends Biotechnol 22, 517-523.
12. Schwabe RF and Brenner DA (2006). Mechanisms of liver injury: I. TNF-α-induced liver injury: role of IKK, JNK, ROS pathways. Am J Physiol Gastrointest Liver Physiol 290, G583-G589.
13. Choi J and Ou JHJ (2006). Mechanisms of liver injury: III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 290, G847-G851.
14. Koulentaki M, Notas G, Petinaki E, Valatas V, Mouzas IA, Castanas E, and Kouroumalis EA (2004). Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Med 15, 35-38.
15. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, and Yalniz M (2005). Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 11, 3260-3263.
16. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C, Pizzigallo E, Conti P, and Vecchiet J (2006). Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 36, 144-150.
17. Odeh M, Sabo E, Srugo I, and Oliven A (2005). Relationship between tumor necrosis factor-α and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med 37, 603-612.
18. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, and George J (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46, 66-73.
19. Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Abd Elatti E, and Ghazal A (2005). Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 21, 527-534.
20. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, and Afdhal NH (2006). Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43, 771-779.
21. Hajeer AH and Hutchinson IV (2000). TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 50, 216-228.
22. Hajeer AH and Hutchinson IV (2001). Influence of TNF alpha gene polymorphisms on TNF alpha production and disease. Hum Immunol 62, 1191-1199.
23. Kroeger KM, Carville KS, and Abraham LJ (1997). The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 34, 391-399.
24. Wilson AG, Symons JA, McDowell TL, McDevitt HO, and Duff GW (1997). Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94, 3195-3199.
25. Wilson AG, di Giovine FS, Blakemore AI, and Duff GW (1992). Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1, 353-359.
26. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, and Rittner C (1998). Tumor necrosis factor-alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 54, 173-177.
27. Bataller R and Brenner DA (2005). Liver fibrosis. J Clin Invest 115, 209-218.
28. Rockey DC and Bissell DM (2006). Noninvasive measures of liver fibrosis. Hepatology 43 (2 (Suppl 1)), S113-S120.
29. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, and Pol S (2007). FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46, 32-36.
30. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, and Rodes J (2002). Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36, 986-992.
31. Wai CT, Greeson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Conjeevaram HS, and Lok AS (2003). A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518-526.
32. Poynard T, Bedossa PMETAVIR and CLINIVIR Cooperative Study Group (1997). Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepatitis 4, 199-208.
33. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, and Stauber RE (2005). Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41, 1376-1382.
34. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, and De Ledinghen V (2005). Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343-350.
35. Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T, and MULTIVIRC Group (2003). Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 48, 146-153.
36. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, et al. (2006). Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 107, 2212-2222.
37. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vegaz O, Morales-Espinosa D, Mendez-Reguera A, Martinez-Tlahuel JL, Gamboa-Dominguezx A, and Arrieta O (2007). Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study. Clin Oncol 19, 197-203.
38. Mocellin S, Rossi CR, Pilati P, and Nitti D (2005). Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16, 35-53.
39. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, and Balkwill FR (2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5, 382-390.
40. Sobin LH and Wittekind C (2002). International Union Against Cancer. TNM Classification of Malignant Tumors, 6th ed, Wiley Liss, New York.
41. Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, and Tsai JH (1993). Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 41, 296-300.
42. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, and Tsai JH (1994). Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 14, 98-102.
43. Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC, and Williams R (1973). Transection of the esophagus for bleeding esophageal varices. Br J Surg 60, 646-649.
44. Morsi MI, Hussein AE, Mostafa M, El-Abd E, and El-Moneim NA (2006). Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gammaglutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci 63, 74-78.
45. Wang YY, Lo GH, Lai KH, Cheng JS, Lin CK, and Hsu PI (2003). Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 66, 593-598.
46. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, and Lai MM (2006). Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 80, 7199-7207.
47. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, and Rusyn I (2007). Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 14, 1182-1190.
48. Giannelli G and Antonaci S (2005). Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 20, 939-944.
49. Feld JJ and Liang TJ (2006). Hepatitis C - identifying patients with progressive liver injury. Hepatology 43, S194-S206.
50. Richardson M, Powell EE, Barrie HD, Clouston AD, Purdie DM, and Jonsson JR (2005). A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet 42, e45.
51. Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4, 540-550.
52. Kusumoto K, Uto H, Hayashi K, Takahama Y, Nakao H, Suruki R, Stuver SO, Ido A, and Tsubouchi H (2006). Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 34, 24-31.
53. Shao RX, Hoshida Y, Otsuka M, Kato N, Tateishi R, Teratani T, Shiina S, Taniguchi H, Moriyama M, Kawabe T, et al. (2005). Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol 11, 1995-1999.
54. Cheng JT, Hsien C, Sun HE, and Tong MJ (2006). The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 101, 2737-2743.
55. Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, Chen HHW, and Guo HR (2004). Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-promoter gene. Cancer Causes Control 15, 657-663.
56. Chen CC, Yang SY, Liu CJ, Lin CL, Liaw YF, Lin SM, Lee SD, Chen PJ, Chen CJ, and Yu MW (2005). Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol 34, 1310-1318.